Search Results
-
COVID-19 vaccines for 5- to 11-year-olds
Answers to frequently asked questions as COVID-19 vaccinations roll out for children as young as 5.
-
When can you vaccinate your kids?
Stanford pediatricians helped conduct clinical trials of COVID-19 vaccines for children. Data from the study will be submitted to the Food and Drug Administration for consideration.
-
Allergies to COVID-19 vaccines mostly mild
In a study of mRNA-based COVID-19 vaccine doses given at Stanford Medicine, vaccine allergies were rare, mild and mostly triggered by a vaccine additive, not the mRNA.
-
Severe COVID-19, autoantibodies linked
A study spearheaded by Stanford researchers indicates that at least 1 in 5 hospitalized COVID-19 patients develops new antibodies that attack their own tissue within a week of admission.
-
Tips for kids’ back-to-school anxiety
Returning to school as the pandemic stretches on may spark anxiety in young students, but there are approaches parents can use to build children’s resilience.
-
Winslow leads national COVID-19 group
A professor of medicine and former Air Force colonel, Winslow temporarily relocated to Washington to head an interagency group responding to this pandemic and preparing for the next one.
-
Evidence COVID-19 causes brain inflammation
A detailed molecular analysis of tissue from the brains of individuals who died of COVID-19 reveals extensive signs of inflammation and neurodegeneration, but no sign of the virus that causes the disease.
-
Pandemic worsens kids’ weight woes
The COVID-19 pandemic has led to a greater incidence of obesity and eating disorders among young people, according to experts at Stanford Children’s Health.
-
Pandemic-linked burnout in pregnancy, neonatal care
A June 2020 survey showed a sharp increase in burnout linked to the global pandemic among health care providers in maternal-fetal and neonatal medicine.
-
Difference in severe versus mild COVID-19
A comprehensive study of immune responses to SARS-CoV-2 associates mild disease with comparatively high levels of antibodies that target the viral spike protein. But all antibodies wane within months.